TreatER webcast seminar – World’s first clinical trial with CDNF: Aiming for a breakthrough in Parkinson's

  1. Welcome and opening words. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc    Video (4:12 min)
  2. Neurotrophic Factors in clinical trials – Brief look to the recent past, present and years to come. Mart Saarma, Professor, Institute of Biotechnology, University of Helsinki     Video (17:46 min)    Slides (pdf)
  3. Cerebral Dopamine Neurotrophic Factor (CDNF)– Potential in prevention of dopamine neuron degeneration and stimulation ofneuron regeneration. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc     Video (21:23 min)    Slides (pdf)
  4. First break with 10 min exercise. Josefa Domingos, Specialist Physiotherapist & EPDA Board Member     Video (9:26 min)
  5. CDNF in the first-in-human clinical trial (Safety) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Magnus Sjögren, Chief Medical Officer, Herantis Pharma Plc    Video (24:18 min)    Slides (pdf)
  6. CDNF in the first-in-human clinical trial (Efficacy) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Per Svenningsson, Principal Investigator, Karolinska University Hospital     Video (23:05 min)     Slides (pdf)
  7. Second break with 10 min exercise. Josefa Domingos, Specialist Physiotherapist & EPDA Board Member     Video (9:11 min)
  8. Clinical data on the investigational drug delivery system used for the CDNF infusion. Jim Baker, Head of QA/RA and Clinical Affairs, Healthcare Division, Renishaw Plc     Video (17:30 min)     Slides (pdf)
  9. Panel discussion on CDNF development for Parkinson’s disease 
    • Per Svenningsson, Professor, Principal Investigator, Karolinska University Hospital
    • Håkan Widner, Professor, Department of Neurology, Skåne University Hospital
    • Filip Scheperjans, Adjunct Professor of Neurology, Helsinki University Hospital
    • Juha Rinne, Professor, Turku PET Centre
    • Göran Lind, Neurosurgeon, Karolinska University Hospital
    • Paul Skinner, General Manager, Renishaw Neuro Solutions Ltd
    • Craig Cook, CEO, Herantis Pharma Plc
    • Alan Whone, Consultant Senior Lecturer in Movement Disorder, University of Bristol    Video (48:16 mi
The CDNF clinical study is part of the TreatER project and has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 732386. For more information please visit the project website www.treater.eu.